UMIN-CTR History
Name： UMIN ID：
| Unique ID issued by UMIN | UMIN000033369 |
|---|---|
| Receipt number | R000038025 |
| Scientific Title | Phase I / IIa clinical trial for patients with hepatitis C or B virus derived liver cirrhosis by CBP / beta catenin inhibitor PRI-724 |
| Date of disclosure of the study information | 2018/07/18 |
| Last modified on | 2022/08/04 14:23:25 |
| No. | Disposal | Last modified on | Item of update | |
|---|---|---|---|---|
| 1 | Insert | 2018/07/12 09:29:09 | ||
| 2 | Update | 2018/07/31 11:04:13 | Recruitment status |
|
| 3 | Update | 2019/01/10 12:51:08 | Co-sponsor |
|
| 4 | Update | 2019/01/10 12:53:30 | Key inclusion criteria Key inclusion criteria |
|
| 5 | Update | 2020/10/27 10:07:04 | 1st name of lead principal investigator Last name of lead principal investigator 1st name of lead principal investigator Last name of lead principal investigator Zip code Last name of contact person Last name of contact person Zip code Co-sponsor Co-sponsor Organization Organization Address Address Tel Secondary IDs Study ID_1 Org. issuing International ID_1 Org. issuing International ID_1 IND to MHLW Institutions |
|
| 6 | Update | 2020/10/27 14:51:51 | Organization |
|
| 7 | Update | 2021/04/05 14:12:34 | Recruitment status Date of IRB Last follow-up date |
|
| 8 | Update | 2021/04/05 14:14:22 | Number of participants that the trial has enrolled |
|
| 9 | Update | 2021/04/05 14:18:18 | Organization Organization |
|
| 10 | Update | 2022/07/04 17:40:28 | Email Email1 |
|
| 11 | Update | 2022/07/04 17:45:37 | Recruitment status Date trial data considered complete Date analysis concluded |
|
| 12 | Update | 2022/07/04 17:47:12 | Publication of results URL related to results and publications |
|
| 13 | Update | 2022/07/08 14:59:45 | URL releasing protocol |
|
| 14 | Update | 2022/07/28 17:58:59 | URL related to results and publications Results Results Results date posted Date of the first journal publication of results Baseline Characteristics Baseline Characteristics Participant flow Participant flow Adverse events Adverse events Outcome measures Outcome measures |
|
| 15 | Update | 2022/08/01 15:17:41 | Results Baseline Characteristics Participant flow Adverse events Outcome measures |
|
| 16 | Update | 2022/08/04 14:23:25 | Results Baseline Characteristics Baseline Characteristics Participant flow Participant flow Adverse events Outcome measures |
